NSC advises against whole-population prostate cancer screening in final recommendation
The UK National Screening Committee (NSC) has advised against whole-population routine NHS prostate cancer screening – recommending instead a ‘targeted screening programme’, involving PSA testing every two years, for a specific group of men who have a pathogenic BRCA2 variant.
The final recommendation, published today, recommended a targeted screening programme for men aged 45 to 61 who have a pathogenic BRCA2 variant with a family history of breast, ovarian, pancreatic, or prostate cancer and said that the best method of identifying and inviting this high-risk group ‘should be evaluated over time’.
The committee concluded that screening is ‘more likely to cause more harm than good’ in the whole population and in men with a family member who has had breast, ovarian or prostate cancer but who do not have a BRCA2 variant.
The main harms of screening include incontinence and erectile dysfunction (impotence) following unnecessary biopsy or treatment, the committee said.
Based on a review of evidence into prostate cancer screening, a modelling study and consultation with stakeholders, the committee:
- does not recommend population screening for this condition
- recommends a targeted screening programme, involving PSA testing every 2 years, for men aged 45 to 61 who have a pathogenic (able to cause disease) BRCA2 variant with a family history of breast, ovarian, pancreatic, or prostate cancer
- recommends that the best method of identifying and inviting the above high-risk group should be evaluated over time
- does not recommend targeted screening for any other risk groups
- will continue to work closely with UK researchers, including the TRANSFORM trial, to address uncertainties in the evidence regarding targeted screening of black men and other risk groups
The UK NSC said: ‘For black men, there is ongoing uncertainty as to whether screening would cause more good than harm.
‘The main harms of prostate cancer screening include incontinence and erectile dysfunction in men who do not need treatment.
‘The UK NSC is hopeful that new evidence, new tests and a better understanding of prostate cancer will support much wider screening in the future.’
In November last year, the committee had already said a draft recommendation that it was set to advise against routine NHS prostate cancer screening.
The positive recommendation for screening men with a BRCA2 gene variant is slightly more restrictive that the draft recommendation, which also included screening men with a BRCA1 variant.
The change was made after discussions with geneticists using published evidence and risk which concluded that those with a BRCA1 variant are not at a sufficiently elevated risk to suggest that benefits of screening would outweigh the harms, the committee said.
Currently, any man aged over 50 can request a PSA test from their GP, but the NSC previously said it does not recommend a screening programme as the test is ‘not accurate enough to detect prostate cancer that needs treatment’.
The committee had last examined the body of evidence in 2020, recommending against introducing a national screening programme as, at that time, ‘the potential harms outweighed the benefits’.
However, it came under increased pressure last year to reconsider PSA testing policy, particularly after Sir Chris Hoy’s announcement that he had been diagnosed with terminal cancer.
RCGP president Professor Victoria Tzortziou Brown said: ‘The NSC’s decision not to recommend population-wide prostate cancer screening reflects the current limitations of PSA testing in identifying cancers that require treatment.
‘We note the recommendation for targeted screening of men aged 45–61 with a BRCA2 mutation, and while we agree that a targeted approach is likely to be most appropriate, identifying all eligible men may prove challenging so, we look forward to hearing more details on how this will be facilitated.
‘GPs want better outcomes for patients with prostate cancer, and we welcome ongoing research – including the Transform Trial – into more accurate tests. Any future developments in screening must be guided by strong evidence of patient benefit.’
Prof Hashim Ahmed, Professor of Urology at Imperial College London, said: ‘The NSC final recommendation following the period of consultation reinforces what the data has consistently shown – that currently the harms unfortunately outweigh the benefits of population level screening for most high-risk groups and the population as a whole.
‘The need for robust data is ever more pressing across all groups of men. The NIHR and Prostate Cancer UK funded TRANSFORM study will be critical to fill the evidence gaps that the NSC have identified.
‘TRANSFORM will hopefully show that we can reduce the harms of over-diagnosis, over-treatment and treatment-related side-effects, but also address the harms of late diagnosis that leads to thousands of men suffering the ill effects of cancer that has spread and thousands still dying of the disease every year.’
Simon Grieveson, assistant director of research at Prostate Cancer UK said: ‘We are deeply disappointed with this final recommendation from the UK NSC which scales back even further from their initial findings.
‘We recognise there is still not enough evidence to support screening for all men at risk, however Prostate Cancer UK is rigorously scrutinising the evidence behind today’s decision and will challenge it where we disagree, as, if accepted by the Government, the programme may only screen a few thousand men each year.’
Visit Pulse Reference for details on 140 symptoms, including easily searchable symptoms and categories, offering you a free platform to check symptoms and receive potential diagnoses during consultations.
Related Articles
READERS' COMMENTS [8]
Please note, only GPs are permitted to add comments to articles
Is there an argument for population screening for BRCA genes?
Given predisposition to a variety of Cancers?
Currently available privately, 23&Me for example.
Doing more harm than good is an old tired arguement.
Patients are individuals and they should have the opportunity to make an informed decision regarding treatment or no treatment based on the best diagnostic evidence available. I sense the dead hand of the treasury looming over this decision.
Patients at my practice will continue to be able to request PSA/DRE as required.
The UK National Screening Committee deserves recognition for resisting the understandable political and emotional pressure to introduce population-wide PSA screening. In an era where public campaigns, celebrity diagnoses, and advocacy narratives can rapidly shape policy, the committee has reaffirmed an essential principle of evidence-based medicine: screening programmes must demonstrate that benefits clearly outweigh harms at population level, not merely that disease can be detected earlier.
The decision to restrict targeted screening to a narrowly defined high-risk BRCA2 population reflects intellectual honesty rather than therapeutic nihilism. It acknowledges what decades of evidence have repeatedly shown: PSA screening remains an imperfect probabilistic tool applied to a biologically heterogeneous disease. The central problem has never been whether PSA can detect prostate cancer, as it can, but whether detecting more prostate cancers improves meaningful outcomes sufficiently to justify the cascade of downstream harms.
Crucially, long-term data from major trials, including ERSPC, show that at 23 years of follow-up all-cause mortality is identical between screened and control groups. This finding is difficult to reconcile with the intuitive assumption that earlier diagnosis should translate into longer life at a population level. If earlier detection through PSA screening meaningfully altered life expectancy across a population, some divergence in overall mortality would reasonably be expected over such a prolonged follow-up period. Its absence forces a deeper reflection: that much of what screening achieves may be earlier labelling and redistribution of disease burden rather than extension of life.
This sits alongside the more familiar observation that any reduction in prostate cancer–specific mortality remains modest in absolute terms, with a high number needed to invite and a substantial burden of overdiagnosis. The real-world consequences of screening are frequently underemphasised: unnecessary biopsies, psychological labelling, overtreatment of indolent disease, urinary incontinence, erectile dysfunction, and the lifelong burden of a cancer diagnosis that may never have become clinically relevant.
Importantly, the conversation must now evolve beyond the simplistic binary of “screen versus do not screen.” The greater challenge lies downstream. PSA-triggered diagnostic and therapeutic pathways themselves may generate additional systemic harm. Increasing evidence suggests that androgen deprivation therapy (ADT), often initiated following PSA-driven diagnoses, carries significant cardiovascular consequences. Emerging data from studies such as REVELUTION indicate accelerated coronary plaque progression associated with GnRH agonists such as leuprolide, potentially helping explain the excess cardiovascular morbidity observed in previous trials.
This matters because a screening programme does not merely detect disease; it creates treatment populations. Earlier detection inevitably increases exposure to interventions, some of which may produce substantial non-cancer morbidity in men who may never have died from prostate cancer itself. The cardiovascular burden of ADT therefore cannot remain conceptually separated from the screening debate. Screening policy should increasingly incorporate not only cancer-specific mortality but also all-cause mortality, competing mortality risks, quality-of-life outcomes, and treatment-induced systemic disease.
The NSC’s caution regarding Black men is also scientifically appropriate. Elevated incidence alone does not automatically justify population screening if the balance between mortality reduction and overdiagnosis remains uncertain. Policy must remain anchored to outcomes rather than epidemiological anxiety.
Perhaps most importantly, this decision reasserts a principle that modern medicine sometimes struggles to defend: more diagnosis is not synonymous with better medicine. In screening, the ethical burden is unusually high because medicine actively intervenes in asymptomatic populations. The threshold for evidence must therefore remain exceptionally rigorous.
It is also striking that even within primary care there remains no real consensus on this issue. General practitioners themselves appear divided, which is in some ways perplexing given the consistency of the long-term data. This ongoing divergence of interpretation reflects not uncertainty in the numbers, but the inherent tension between earlier detection and the risks of overdiagnosis, overtreatment, and downstream harm. It also underscores how easily screening debates become shaped by intuition rather than outcomes.
The future of prostate cancer screening will likely depend not on broader PSA deployment, but on better risk stratification: genomic profiling, MRI-integrated pathways, molecular biomarkers, and improved discrimination between indolent and aggressive disease. Until then, restraint is not failure. It is responsible medicine.
The NSC should therefore be commended not only for what it recommended, but for what it resisted.
I disagree. We already monitor patients with borderline or rising PSA, often those who have had private screening, before committing to treatment. The move away from invasive biopsies for all patients with raised PSA to non invasive imaging and PSA monitoring has changed the game. An NHS screening program would stop the health inequality between those who are better informed or have access to private screening and those who do not. Patients should be talked through management options and the risk/benefit analysis and be able to make their own informed decision. I suspect the data from modern management was not sufficiently robust and not given enough weight. That and the dead hand of the treasury …
Data from the last 23 years will, by definition, include results from out of date practices such as non targeted TRUS and TRUSB biopsy techniques with the associated high risk of complications. Modern techniques starting with PSA/DRE, PSA monitoring, mpMRI and targeted transperineal biopsy have changed the game and rendered much of the old data irrelevant. Harms that once justification inaction have now been largely engineered out.
The recent Swedish study published in the NEJ shows the way forward.
In answer to Dave Haddock, the NSC announcement to cut back on the national Prostate Cancer Screening Programme (we are already compelled to do PSA up to about every 2 months by statements from Urology specialists) gives a clear go-ahead to national BRCA gene screening for all men who express an interest in PSA testing. We can no longer even put them off by offering to do blood test and DRE together, since apparently the DRE is not sensitive enough. i am not sure if this is a shot in the foot for the control of expenditure on screening, or a shot in the arm for the movement towards universal global DNA/gene screening of the modern ‘NHS’, but the direction and costs have effectively been taken out of the hands of GPs now. All that is left is How often do we need to do PSA on BRCA positive patients? And : What other tumour markers should they also have tested how often ?
Great comment Dr Cervoni, thank you.
The Screening debate distracts from the issue of why are NHS treatment outcomes lagging many other Countries, and what can be done to catch up?
Great comment Dr Cervoni, thank you.
The debate about screening has distracted from the problem of why NHS treatment outcomes are still lagging comparable healthcare systems, and what can be done to improve?